Catherine X. Pan-Giordano

Corporate Global Expansion – M&As, JVs and Investments

• Represented a global private equity firm in its $5 billion investments in Alibaba Group, 360buy.com and Xiaomi Corporation 
• Represented Eddingpharm Group, a leading pharmaceutical contract sales company in China, in connection with its acquisition of certain pharmaceutical product rights in China from Eli Lilly 
• Represented Yili Group, the largest dairy products company in Asia, in its bidding for Stonyfield, the No. 1 organic yogurt maker in the United States, a subsidiary of Danone 
• Represented Fosun Group in various strategic investments and acquisitions in the United States  
• Representing CDH Investments, a top Chinese PE firm, in connection with multiple acquisitions and investments 
• Represented a leading non-profit biomedical research organization in the United States in connection with its proposed joint venture and collaborative research initiatives with business partners and universities in China 
• Representing a Hong Kong Stock Exchange listed real estate conglomerate in connection with its acquisitions of multiple real estate portfolios in the United States, including retirement living facilities, student housing projects and other commercial and mixed use properties
• Represented multiple prestigious private schools in the United States in connection with partnership initiatives with private schools and investors in China
• Represented a publicly traded Chinese company in connection with its participation in the Series C financing of a U.S.-based technology company through a Hong Kong subsidiary and the subsequent redomestication of this company from Delaware to Singapore
• Represented certain shareholders of a Minnesota-based private marketing and sales company in the proposed sale of their controlling interests in the company to a Chinese public company
• Represented Atlantic Power in its $1 billion cross-border acquisition of Capital Power Income and related financings 
• Represented Ninebot Limited, a portfolio company of Xiaomi Technologies and Sequoia Capital, in business combination with Segway, Inc. and related financing transactions
• Represented Fantasia Group, the largest Chinese property management conglomerate, in its U.S. real estate joint venture deals 
• Represented a U.S. maritime technology company in its sale to a Beijing-based Chinese public company
• Represented a private-equity arm of a Chinese public company in the potential acquisition of a public traded US company
• Assisting one of the largest railway construction companies in the world in the first high-speed rail project in the U.S.
• Representing a leading infrastructure construction company in China in its U.S. expansion
• Represented significant stockholders of China Biologic Products, Inc. (NASDAQ: CBPO) in sale of approximately $40 million worth of shares to Warburg Pincus 
• Representing numerous technology companies from China’s Silicon Valley (“Z Park”) in acquiring technologies, brands and other assets in the U.S. through acquisitions and investments
• Representing one of the largest dairy products companies in China in its expansion in the U.S. 
• Represented PRTM, a global management consulting firm and a subsidiary of PWC, in its acquisitions of various consulting firms in Asia 
• Represented META Group in its $170 million merger with Green Falcon, a merger sub of Gartner 
• Represented a NASDAQ listed company in the establishment of an equity joint venture in Shanghai and a representative office in Shenzhen
• Represented a U.S. hospitality group in its joint venture with Shanghai Chengtou Holding Co., Ltd., one of the largest real estate developers in China 
• Represented Accion International, one of the world’s largest micro-finance organizations, in its joint venture projects with the World Bank and IFC 

Financing – Trade Finance, Credit Facilities and other Banking Transactions

• Represented Agricultural Bank of China in its U.S.-based credit facilities transactions with various corporate lenders 
• Represented Bank of China in its U.S.-based credit facilities transactions with various Chinese companies 
• Represented several Chinese banks’ New York branches in designing and documenting various cross-border banking products 
• Represented several Chinese banks in their yuan credit facility financing transactions guaranteed by USD deposits
• Represented numerous corporate clients in credit facility transactions with Citibank

Capital Markets – IPOs, Secondary Offerings and PIPEs 

• Represented a significant selling stockholder in the IPO of Alibaba Group Holding Ltd. (NYSE: BABA)
• Represented Deutsche Bank Securities and a co-underwriter in the $186 million public offering of Aspen Technology 
• Represented Credit Suisse, Morgan Stanley and Deutsche Bank Securities in the $160 million IPO of SS&C Technologies Holdings 
• Represented an Argentine national electricity company in its Regulation S and Regulation D exchange offering in the U.S. and overseas 
• Represented a U.S. company in its overseas casino condominium resort units offering and development projects in Asia, including securities law compliance matters 
• Represented a European video game company in its acquisition of a U.S. public company and stock exchange listing 
• Represented issuer in the $108 million secondary public offering of Puda Coal Inc. (NYSE: PUDA)
• Represented the largest private Chinese printing company, Duoyuan Printing, Inc., in its $24 million PIPE offering in the U.S. 
• Represented numerous U.S. domestic issuers and Chinese foreign private issuers in their SEC filings and Sarbanes-Oxley Act compliance, including preparing S1, SB2, 10K, 10Q, 8K, 14f1, Section 16 filings, 20F, 6K and Confidential Treatment Request 
• Represented several U.S. listed Chinese companies in their going private and going dark transactions

Solving Problems – Risk Management, Litigation Prevention and Dispute Resolution

• Winning post-closing disputes regarding net working capital and earn-out payments after several M&A transactions
• Solving a founders dispute in the months preceding a major IPO
• Solving shareholders disputes following several PE funding transactions 
• Freeing up minority shareholders’ restricted shares in controlling shareholder dominated corporations or asserting minority rights in protection of founders and entrepreneurs
• Represented various Chinese public companies and their audit committees, directors and executives officers in internal and SEC investigations, securities class actions and derivative lawsuits 
• Representing universities and research institutions in NIH, NSF, DOJ and FBI investigations relating to federal research grants
• Representing researchers and faculty members across the U.S. in NIH, NSF, DOJ and FBI investigations relating to China ties